| JAK2基因突变与骨髓增生性疾病的关系 |
| |
| 引用本文： | 李舟,朱平. JAK2基因突变与骨髓增生性疾病的关系[J]. 白血病．淋巴瘤, 2007, 16(1): 70-72 |
| |
| 作者姓名： | 李舟 朱平 |
| |
| 作者单位： | 100034,北京大学第一医院血液科;100034,北京大学第一医院血液科 |
| |
| 摘 要： | 骨髓增生性疾病（MPD）中真性红细胞增多症（PV）、特发性血小板增多症（ET）、特发性骨髓纤维化（IMF）发现蛋白酪氨酸激酶（JAK2）基因上有一个碱基突变JAK2 V617F，突变明显与PV、ET和IMF的发生有关，这一发现可能成为诊断这类综合征的一种方式，也为寻找新的药物治疗MPD提供了明确的作用目标，同时还为研究细胞生长紊乱和细胞功能紊乱提供新的研究思路。
|
| 关 键 词： | 骨髓增殖性疾病 红细胞增多症 真性 血小板增多 出血性 骨髓纤维化 JAK2 V617F突变 |
| 文章编号： | 1009-9921（2007）01-0070-03 |
| 收稿时间： | 2006-01-18 |
| 修稿时间： | 2006-03-12 |
Relationship of JAK2 V617F mutation and myeloproliferative disorder |
| |
| LI Zhou,ZHU Ping. Relationship of JAK2 V617F mutation and myeloproliferative disorder[J]. Journal of Leukemia & Lymphoma, 2007, 16(1): 70-72 |
| |
| Authors: | LI Zhou ZHU Ping |
| |
| Affiliation: | Depart-merit of Hematology, The First Hospital of Peking University, Beijing 100034, China |
| |
| Abstract: | A Jak2V617F mutation has been described in the vast majority of patients with myeloprolifera-tive disorder (MPD) including polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF). The single, somatic mutation in the protein tyrosine kinase janus kinase 2 (JAK2) appears responsible for many of the features of PV, ET, and IMF, the finding that promises to impact the diagnosis and new medical treatment of patients with these disorders and to spur additional research into the origins of dysregulated cell growth and function. |
| |
| Keywords: | Myeloproliferative disorder Polycythemia vera Thrombocythemia hemorrhagic Myelofibrosis Jak2V617F mutation |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
| 点击此处可从《白血病．淋巴瘤》浏览原始摘要信息 |
|
点击此处可从《白血病．淋巴瘤》下载全文 |
